Used for: Follicular lymphoma · Diffuse large B-cell lymphoma (DLBCL) · Chronic lymphocytic leukemia (CLL) · 2 more
How to pay the least
Ask for the cash price
Rituxan Hycela
Rituxan Hycela is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold.
What to do
Ask your pharmacy for Rituxan Hycela’s cash price, and one or two other pharmacies too.
Rituxan Hycela’s savings card works only with insurance from a job or one you bought.
Other ways
Free from the maker, if you qualify Genentech Patient Foundation. Do not have insurance coverage for their Genentech medicine and their household makes less than $150,000 per year Or call (888) 941-3331.
“With the Genentech Oncology Co-pay Assistance Program, eligible patients with commercial insurance could pay as little as $0 per treatment for RITUXAN HYCELA.”
From the maker’s offer on rituxanhycela.com, checked November 17, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.
Maker’s card or discount card?
A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.
Authorized generic
There isn’t one.
Not soldThere isn’t one
Regular generic
Rituxan Hycela is a biologic. Biologics don’t have generics, but some have biosimilars or an unbranded version from the same maker. Ask your pharmacist or prescriber whether one is sold.
RITUXAN HYCELA is a combination of rituximab, a CD20-directed cytolytic antibody, and hyaluronidase human, an endoglycosidase, indicated for the treatment of adult patients with:
Follicular Lymphoma (FL)
Relapsed or refractory, follicular lymphoma as a single agent
Previously untreated follicular lymphoma in combination with first line chemotherapy and, in patients achieving a complete or partial response to rituximab in combination with chemotherapy, as single-agent maintenance therapy
Non-progressing (including stable disease), follicular lymphoma as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy
Diffuse Large B-cell Lymphoma (DLBCL)
Previously untreated diffuse large B-cell lymphoma in combination with cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) or other anthracycline-based chemotherapy regimens
Chronic Lymphocytic Leukemia (CLL)
Previously untreated and previously treated CLL in combination with fludarabine and cyclophosphamide (FC)
Limitations of Use:
Initiate treatment with RITUXAN HYCELA only after patients have received at least one full dose of a rituximab product by intravenous infusion..
RITUXAN HYCELA is not indicated for the treatment of non-malignant conditions.
Source: the FDA label for Rituxan Hycela (Genentech, Inc.), September 23, 2026. Full label on DailyMed
Good to know
“Commercial insurance” means a plan from a job, from the marketplace, or one you buy yourself. A retiree plan that’s part of Medicare counts as Medicare. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.
Most cards need a sign-up on the maker’s site, and many work only if your plan covers the drug. Then give the card’s details to your pharmacy.
Don’t stop or change a medicine without talking to your pharmacist or prescriber.
Prices checked November 17, 2026. Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/rituxan-hycela/